CN114746753A - 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途 - Google Patents

通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途 Download PDF

Info

Publication number
CN114746753A
CN114746753A CN202080082295.5A CN202080082295A CN114746753A CN 114746753 A CN114746753 A CN 114746753A CN 202080082295 A CN202080082295 A CN 202080082295A CN 114746753 A CN114746753 A CN 114746753A
Authority
CN
China
Prior art keywords
range
akr1c3 enzyme
akr1c3
content
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080082295.5A
Other languages
English (en)
Inventor
段建新
谢燕彬
姬金凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Original Assignee
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Ascentawits Pharmaceutical Technology Co ltd filed Critical Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Publication of CN114746753A publication Critical patent/CN114746753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

通过前列腺素含量来关联AKR1C3酶表达水平及筛选给药用途，具体而言就是：测量前列腺素含量来关联生物试样中的AKR1C3酶表达水平的高低；测量施用干扰药物前后前列腺素含量变化、含量变化率来关联生物试样中AKR1C3酶表达水平的高低。测量AKR1C3酶表达水平的组件，其包含：与生物试样接触发生反应，根据反应的信号来定量或半定量关联该生物试样中前列腺素含量的构件；对照比较构件，用于比较反应的信号来对照比较得出所述生物试样中前列腺素含量的含量、施用干扰药物前后前列腺素含量的含量变化、含量变化率所对应的AKR1C3酶表达水平的高低。给药装置，其包含：测量AKR1C3酶表达水平的组件；给药组件，其含有AKR1C3酶活化的抗癌前药。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080082295.5A 2019-12-03 2020-12-03 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途 Pending CN114746753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019112197422 2019-12-03
CN201911219742.2A CN112904026A (zh) 2019-12-03 2019-12-03 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途
PCT/CN2020/133538 WO2021110085A1 (zh) 2019-12-03 2020-12-03 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途

Publications (1)

Publication Number Publication Date
CN114746753A true CN114746753A (zh) 2022-07-12

Family

ID=76103778

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911219742.2A Pending CN112904026A (zh) 2019-12-03 2019-12-03 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途
CN202080082295.5A Pending CN114746753A (zh) 2019-12-03 2020-12-03 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911219742.2A Pending CN112904026A (zh) 2019-12-03 2019-12-03 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途

Country Status (11)

Country Link
US (1) US20230017359A1 (zh)
EP (1) EP4071473A4 (zh)
JP (1) JP2023505438A (zh)
KR (1) KR20220107273A (zh)
CN (2) CN112904026A (zh)
AU (1) AU2020396113A1 (zh)
BR (1) BR112022010833A2 (zh)
CA (1) CA3163127A1 (zh)
IL (1) IL293468A (zh)
TW (1) TWI785428B (zh)
WO (1) WO2021110085A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022178821A1 (en) * 2021-02-26 2022-09-01 Ascentawits Pharmaceuticals, Ltd. Use of akr1c3-activated compound
EP4365182A1 (en) * 2021-06-11 2024-05-08 Ascentawits Pharmaceuticals, Ltd. Gemcitabine anticancer derivative and anticancer pharmaceutical use
WO2023237080A1 (zh) * 2022-06-10 2023-12-14 深圳艾欣达伟医药科技有限公司 Akr1c3酶激活前药治疗癌症患者的方法
WO2024051792A1 (zh) * 2022-09-09 2024-03-14 深圳艾欣达伟医药科技有限公司 Ast-3424联用治疗白血病及淋巴瘤
WO2024125595A1 (zh) * 2022-12-14 2024-06-20 深圳艾欣达伟医药科技有限公司 吉西他滨抗癌衍生物及其抗癌医药用途和制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044686A1 (en) * 2008-10-17 2010-04-22 Auckland Uniservices Limited Akr1c3 as a biomarker, methods of selecting and treating patients based upon an akr1c3 profile and compounds for use therein
CN102836433A (zh) * 2011-06-23 2012-12-26 北京大学 逆转或降低食管癌放疗抗性的增敏剂、筛选方法及其用途
WO2016061342A1 (en) 2014-10-17 2016-04-21 Albemarle Corporation Methods for quantifying zinc content of fluids
KR102398323B1 (ko) 2015-03-10 2022-05-16 아센타위츠 파마슈티컬즈 리미티드 Dna 알킬화제
CN112142692A (zh) 2015-04-02 2020-12-29 深圳艾欣达伟医药科技有限公司 硝基苄基衍生物抗癌试剂
ES2781398T3 (es) 2015-11-16 2020-09-01 Obi Pharma Inc (R)- y (S)-1-(3-(3-N,N-dimetilaminocarbonil)fenoxil-4-nitrofenil)-1-etil-N,N¿-bis (etilen)fosforamidato, composiciones y métodos para sus usos y preparación
WO2018148721A1 (en) * 2017-02-13 2018-08-16 Texas Tech University System Highly selective akr1c3 inhibitors and methods of use thereof
EP3421483A1 (en) * 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN109833321A (zh) * 2017-11-28 2019-06-04 中国科学院大连化学物理研究所 一种逆转肝癌细胞对sorafenib耐药性的药物组合物
WO2019190331A1 (en) 2018-03-29 2019-10-03 Achilles Medical Limited Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders
WO2022048492A1 (zh) * 2020-09-02 2022-03-10 深圳艾欣达伟医药科技有限公司 一种akr1c3检测方法、检测akr1c3的诊断试剂盒及其用途

Also Published As

Publication number Publication date
EP4071473A1 (en) 2022-10-12
CN112904026A (zh) 2021-06-04
BR112022010833A2 (pt) 2022-08-23
US20230017359A1 (en) 2023-01-19
AU2020396113A1 (en) 2022-07-14
JP2023505438A (ja) 2023-02-09
WO2021110085A1 (zh) 2021-06-10
CA3163127A1 (en) 2021-06-10
IL293468A (en) 2022-08-01
TW202128187A (zh) 2021-08-01
EP4071473A4 (en) 2024-01-10
KR20220107273A (ko) 2022-08-02
TWI785428B (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
CN114746753A (zh) 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途
Wang et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway
Wu et al. Lipid peroxidation plays an important role in chemotherapeutic effects of temozolomide and the development of therapy resistance in human glioblastoma
O’Brien et al. Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging
Giallongo et al. CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
Israel et al. Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat
CN102353732A (zh) 一种珍龙醒脑制剂的质量检测方法
Sun et al. Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines
CA3105884C (en) Use of compound in drug for preventing, treating, or alleviating pain
Billimoria et al. Senescence in cancer: Advances in detection and treatment modalities
Chang et al. A mitochondria-targeted fluorescent probe for monitoring NADPH overproduction during influenza virus infection
Maier et al. A Novel Screening Approach for the Discovery of Biologically Active Secondary Metabolites II. Application Studies with Pure Metabolites
Cao et al. The pharmaceutical excipient PEG400 affect the absorption of baicalein in Caco‐2 monolayer model by interacting with UDP‐glucuronosyltransferases and efflux transport proteins
Du et al. High-throughput metabolomic method based on liquid chromatography: high resolution mass spectrometry with chemometrics for metabolic biomarkers and pathway analysis to reveal the protective effects of baicalin on thyroid cancer
Qi et al. Simultaneous quantification of pirarubicin, doxorubicin, cyclophosphamide, and vincristine in human plasma of patients with non-Hodgkin's lymphoma by LC–MS/MS method
Tron et al. Tacrolimus: does direct glucuronidation matter? An analytical and pharmacological perspective
Lee et al. Inhibitory effect of berberine from Coptidis rhizoma on melanin synthesis of murine malignant melanoma
JPH07146296A (ja) 多重抗癌剤耐性を検定する方法
Fritz et al. Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance?
Liu et al. Development of a simple LC-MS/MS method for determination of rebamipide in human plasma and its application to a bioequivalence study
Arruda et al. Zidovudine glycosylation by filamentous fungi leads to a better redox stability and improved cytotoxicity in b16f10 murine melanoma cells
CN106546690B (zh) 一种20(R)-人参皂苷Rg3的质量标准检测方法
Roh et al. A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres
CN108721260B (zh) 海桐花苷a1在制备治疗人肝癌的药物方面的应用
Antonyuk et al. Use of lectins as vector molecules for delivery of drugs to cells and tissues. Report 2.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination